# EDGAR Filing Document

**Accession Number:** 0001859007
**File Stem:** 0000000000-23-001409
**Filing Date:** 2023-2
**Character Count:** 10618
**Document Hash:** a8dce8e7d6608f7c5ab7d828275747a9
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-23-001409.hdr.sgml**: 20231121

**ACCESSION NUMBER**: 0000000000-23-001409

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20230210

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ZyVersa Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001859007
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 862685744
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD

**BUSINESS ADDRESS:**
- **STREET 1:** 217 W. MAIN STREET
- **CITY:** SOMERVILLE
- **STATE:** NJ
- **ZIP:** 08876
- **BUSINESS PHONE:** 908-370-5102

**MAIL ADDRESS:**
- **STREET 1:** 217 W. MAIN STREET
- **CITY:** SOMERVILLE
- **STATE:** NJ
- **ZIP:** 08876

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Larkspur Health Acquisition Corp.
- **DATE OF NAME CHANGE:** 20210426
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001493152-22-036164

## Text-Extract

```

United States securities and exchange commission logo

                              February 10, 2023

       Stephen C. Glover
       Chief Executive Officer
       ZyVersa Therapeutics, Inc.
       2200 N. Commerce Parkway, Suite 208
       Weston, FL 33326

                                                        Re: ZyVersa
Therapeutics, Inc.
                                                            Amendment No. 1 to
Registration Statement on Form S-1
                                                            Filed February 1,
2023
                                                            File No. 333-268934

       Dear Stephen C. Glover:

             We have reviewed your amended registration statement and have the
following
       comments. In some of our comments, we may ask you to provide us with
information so we
       may better understand your disclosure.

              Please respond to this letter by amending your registration
statement and providing the
       requested information. If you do not believe our comments apply to your
facts and
       circumstances or do not believe an amendment is appropriate, please tell
us why in your
       response.

              After reviewing any amendment to your registration statement and
the information you
       provide in response to these comments, we may have additional comments.
Unless we note
       otherwise, our references to prior comments are to comments in our
January 4, 2023 letter.

       Amendment No. 1 to Registration Statement on Form S-1, filed on February
1, 2023

       Cover Page

   1.                                                   We note your disclosure
on page 55 and elsewhere throughout your registration statement,
                                                        that the conversion
price of the PIPE Shares and the Series B Shares will be reset to the
                                                        price that your shares
will be sold for in this offering, but not below a price of $2.00 for
                                                        the PIPE Shares and
$7.00 for the Series B Shares. We also note your disclosure that the
                                                        exercise price of the
PIPE Warrants will be reset to the price that your shares are sold for
                                                        in this offering, but
not below a price of $2.00. Please make these disclosures
                                                        prominently on the
cover page of the registration statement.
 Stephen C. Glover
FirstName LastNameStephen
ZyVersa Therapeutics, Inc. C. Glover
Comapany10,
February   NameZyVersa
            2023         Therapeutics, Inc.
February
Page 2 10, 2023 Page 2
FirstName LastName
Management's Discussion and Analysis of Financial Condition and Results of
Operations
Post-Business Combination Capital Needs, page 72

2.       We note your response to prior comment 6 noting that you expect to
raise capital through
         issuances of registered shares of your common stock to new and
existing investors and
         your disclosure on page 124 noting that you intend to raise additional
capital in the future
         to fund continued development. Please revise your disclosure here and
in your risk factor
         section to discuss the effect that this offering will have on your
ability to raise additional
         capital.
General

3.       We note your disclosure that the company's stock price as of January
31, 2023, was $1.84,
         resulting in the Series A Preferred Stock and PIPE warrants being out
of the money, based
         on the adjusted conversion and exercise prices of $2.00 per share.
However, we also note
         that the company's stock price since February 2, 2023, has been above
$2.00 per share.
         Please update your disclosure throughout the prospectus regarding
potential profit
         accordingly.
4.       We note your disclosure on page 54 that the Series A Certificate of
Designation includes
         the right for the issuer to redeem the PIPE Shares at 120% of the
issue price of the PIPE
         Shares then outstanding. We also note the Form S-1 filed by the
company on January 27,
         2023, relating to a primary offering of common stock and warrants in
which the company
         has stated its intention to use approximately $10.4 million of
proceeds raised in that
         offering to redeem all of the PIPE Shares pursuant to the Series A
Certificate of
         Designation. Please revise this prospectus to discuss the interaction
of these two
         registration statements, disclosing that the PIPE shareholders will
likely have their
         shares redeemed by the company at 120% of the issue price and that
they will then, in
         fact, make a profit on such shares. Please carry this disclosure
throughout the prospectus
         in all places in which you discuss the potential profit per PIPE
share.
       Please contact Joshua Gorsky at 202-551-7836 or Laura Crotty at
202-551-7614 with
any questions.

                                                                Sincerely,

                                                                Division of
Corporation Finance
                                                                Office of Life
Sciences
cc:      Jared Kelly

```

### Attached PDF Documents

**Attachment 1:** `filename1`

![img-0.jpeg](img-0.jpeg)

CORPORATION FINANCE

# UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

February 10, 2023

Stephen C. Glover  
Chief Executive Officer  
ZyVersa Therapeutics, Inc.  
2200 N. Commerce Parkway, Suite 208  
Weston, FL 33326

# **Re: ZyVersa Therapeutics, Inc.**  
**Amendment No. 1 to Registration Statement on Form S-1**  
**Filed February 1, 2023**  
**File No. 333-268934**

Dear Stephen C. Glover:

We have reviewed your amended registration statement and have the following comments. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure.

Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe our comments apply to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response.

After reviewing any amendment to your registration statement and the information you provide in response to these comments, we may have additional comments. Unless we note otherwise, our references to prior comments are to comments in our January 4, 2023 letter.

Amendment No. 1 to Registration Statement on Form S-1, filed on February 1, 2023

# Cover Page

1. We note your disclosure on page 55 and elsewhere throughout your registration statement, that the conversion price of the PIPE Shares and the Series B Shares will be reset to the price that your shares will be sold for in this offering, but not below a price of $2.00 for the PIPE Shares and $7.00 for the Series B Shares. We also note your disclosure that the exercise price of the PIPE Warrants will be reset to the price that your shares are sold for in this offering, but not below a price of $2.00. Please make these disclosures prominently on the cover page of the registration statement.

Stephen C. Glover
ZyVersa Therapeutics, Inc.
February 10, 2023
Page 2

# Management's Discussion and Analysis of Financial Condition and Results of Operations
Post-Business Combination Capital Needs, page 72

2. We note your response to prior comment 6 noting that you expect to raise capital through issuances of registered shares of your common stock to new and existing investors and your disclosure on page 124 noting that you intend to raise additional capital in the future to fund continued development. Please revise your disclosure here and in your risk factor section to discuss the effect that this offering will have on your ability to raise additional capital.

# General

3. We note your disclosure that the company's stock price as of January 31, 2023, was $1.84, resulting in the Series A Preferred Stock and PIPE warrants being out of the money, based on the adjusted conversion and exercise prices of $2.00 per share. However, we also note that the company's stock price since February 2, 2023, has been above $2.00 per share. Please update your disclosure throughout the prospectus regarding potential profit accordingly.
4. We note your disclosure on page 54 that the Series A Certificate of Designation includes the right for the issuer to redeem the PIPE Shares at 120% of the issue price of the PIPE Shares then outstanding. We also note the Form S-1 filed by the company on January 27, 2023, relating to a primary offering of common stock and warrants in which the company has stated its intention to use approximately $10.4 million of proceeds raised in that offering to redeem all of the PIPE Shares pursuant to the Series A Certificate of Designation. Please revise this prospectus to discuss the interaction of these two registration statements, disclosing that the PIPE shareholders will likely have their shares redeemed by the company at 120% of the issue price and that they will then, in fact, make a profit on such shares. Please carry this disclosure throughout the prospectus in all places in which you discuss the potential profit per PIPE share.

Please contact Joshua Gorsky at 202-551-7836 or Laura Crotty at 202-551-7614 with any questions.

Sincerely,

Division of Corporation Finance
Office of Life Sciences

cc: Jared Kelly